Clinical example of long-term control of disseminated signet-ring cell carcinoma of the stomach against the background of chemotherapy of the second line of treatment in combination with bevacizumab
The standard of treatment of the second line of disseminated stomach cancer is palliative chemotherapy with paclitaxel in combination with ramucirumab. Vascular endothelial growth factor A (VEGF-A) is a key regulator of blood vessel growth and its connection to the corresponding receptors of VEGFR1/...
Main Authors: | T. A. Titova, N. S. Besova, E. V. Artamonova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2019-12-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/5308 |
Similar Items
-
Clinical example of enhancing efficacy of paclitaxel by combining it with ramuchirumabin in the second-line chemotherapy of disseminated gastric cancer
by: T. A. Titova, et al.
Published: (2019-06-01) -
Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma
by: Kaseb AO, et al.
Published: (2016-02-01) -
Ramucirumab combined with paclitaxel as the second-line chemotherapy for elderly patients with disseminated gastric cancer
by: T. A. Titova, et al.
Published: (2018-07-01) -
Results of the use of ramucirumab in combination with irinotecan and fluoropyrimidines in the second-line chemotherapy for disseminated gastric cancer
by: N. S. Besova, et al.
Published: (2019-06-01) -
Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer
by: Hironaga Satake, et al.
Published: (2020-11-01)